SOUTH SAN FRANCISCO, Calif., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Leerink Swann Global Healthcare Conference on Thursday, February 14 at 3:00 p.m. ET (12:00 p.m. PT).
Donald J. Santel, Chief Executive Officer of Hyperion, will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. For more information, please visit www.hyperiontx.com
Shari Annes, Investor Relations (650) 888-0902 Kristie Kuhl, Media Relations (203) 556-7417
Hyperion Therapeutics, Inc.
South San Francisco, California, UNITED STATES
Shari Annes, Investor Relations (650) 888-0902 Kristie Kuhl, Media Relations (203) 556-7417
Symbol: HPTX
Day's Range: 20.45-21.22
Open: 20.72
Previous Close: 20.66
TSO: 20,042,000
Market Cap: 415.87M
Day's Volume: 45,657